The COVID-19 pandemic is tearing through the country right as we are starting into the holiday season, but the wheels of science including cell biology keep going and we keep reading all the great work. What news or papers caught your eye? Here are some of the things I have on my list of reading. […]
Weekend cell biology reads: Mesoblast COVID-19 deal, pubs Read More »
IPS cell research is a growing area of promise for regenerative medicine. These stem cells, also known as iPSCs or more formally as Induced Pluripotent Stem Cells, are engineered cells that are programmed to function the same way as embryonic stem cells. They can be differentiated into possibly any type of cell that is needed for
Overview of IPS cell prospects for clinical impact Read More »
When you sit down to read science on the weekends lately, assuming you are not primarily a COVID-19 researcher, how much COVID stuff seeps into your reading? As I was going over some of this year’s recommended weekly reads posts here on The Niche, I’ve realized that an increasing amount of COVID-19 research has joined
Recommended reads: PSC, COVID, FDA pledge, sci jobs Read More »
Graft-versus-host disease (GVHD) is counterintuitive In the weeks and months following a transplant, a major concern is the recipient’s immune system rejecting the “foreign” biological material. But in GVHD, the opposite happens: transplanted tissue unleashes a horde of T cells that spark a cascade of inflammation, within 100 days. Typically, GVHD follows a bone marrow
Mesoblast MSCs Quell Peds GvHD; On Road to FDA Approval? Read More »
Organoids are providing a novel avenue into the pathogenesis of COVID-19 and novel models for drug screening. A number of new preprints on respiratory organoids shed new light in this area. They were highlighted in a Nature newsy piece, Mini organs reveal how the coronavirus ravages the body. It’s a challenge to study COVID-19 infections because just infecting
Weekly reads: organoids, COVID-19, CIRM & cool new pubs Read More »
Once upon a time this blog and major outlets around the world were regularly writing about a Japanese stem cell researcher named Haruko Obokata (小保方 晴子). Whatever happened to Obokata and the other folks directly involved in STAP cell research? First, a bit of background because maybe still a few people never heard of STAP cells
Whatever happened to the STAP cell scientists including Haruko Obokata? Read More »
ViaCyte is one of the most exciting stem cell and regenerative medicine biotech companies so I like to try to check in with them regularly. Today’s post is my new interview with ViaCyte leader Paul Laikind on recent developments. We had a great chat about the science and how things are looking upbeat for the
ViaCyte Q&A: CRISPR Tx quick progress, ongoing diabetes trial, & more Read More »
By Jeanne Loring A stem cell anniversary: 18 years ago today that the US initiated funding of human embryonic stem cell research. August 9, 2001 was a big day for me. George W. Bush was the US president, and it was an understatement to say that I was not very fond of his policies; but
Jeanne Loring: hES cell research, Bush, & her career Read More »
Could He Jiankui have faked part or all of his CRISPR babies story? If so, how? Why? Or to put it another way, almost everyone seems to be assuming the story is real, but should we be more skeptical? Should we flip things around and assume the story isn’t entirely kosher until proven otherwise? I once
History tells us to be more skeptical of He Jiankui’s CRISPR baby story Read More »
In Parkinson’s Disease patients develop neurological dysfunction as they lose a special kind of brain cell called dopaminergic (or dopamine) neurons. While a number of different approaches to this disease have been studied for decades, nothing has proven particularly successful in slowing its progression. As a result there has been a big need for novel thinking
Hope on Parkinson’s front: Japan IPSC trial 1st patient Read More »